Michael Joseph Krowka

Michael Joseph Krowka's AcademicInfluence.com Rankings

Philosophy

#7715

World Rank

#10965

Historical Rank

Logic

#4753

World Rank

#6080

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Michael Joseph Krowka Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael Joseph Krowka's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Haemodynamic definitions and updated clinical classification of pulmonary hypertension (2019) (2124)
Diagnosis and differential assessment of pulmonary arterial hypertension. (2004) (999)
Pulmonary–Hepatic vascular Disorders (PHD) (2004) (734)
Hepatopulmonary syndrome--a liver-induced lung vascular disorder. (2008) (576)
Pulmonary hemodynamics and perioperative cardiopulmonary‐related mortality in patients with portopulmonary hypertension undergoing liver transplantation (2000) (513)
Natural history of hepatopulmonary syndrome: Impact of liver transplantation (2005) (415)
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. (2004) (398)
Hepatopulmonary syndrome and portopulmonary hypertension: A report of the multicenter liver transplant database (2004) (389)
Pulmonary complications of bone marrow transplantation. (1985) (388)
Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin (1998) (356)
Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation (2003) (353)
Portopulmonary hypertension: Results from a 10‐year screening algorithm (2006) (316)
Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. (1993) (288)
Portopulmonary hypertension and hepatopulmonary syndrome (2004) (276)
Survival in Portopulmonary Hypertension: Mayo Clinic Experience Categorized by Treatment Subgroups (2008) (275)
Hepatopulmonary syndrome. Current concepts in diagnostic and therapeutic considerations. (1994) (274)
Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension (1999) (255)
International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. (2016) (254)
Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. (1996) (245)
Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. (2008) (237)
Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanning. (2000) (231)
Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. (1998) (230)
Hepatic hydrothorax: pathogenesis, diagnosis, and management. (1999) (226)
Clinical risk factors for portopulmonary hypertension (2008) (225)
Portopulmonary hypertension: a report from the US-based REVEAL Registry. (2012) (222)
Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates. Screening by two-dimensional contrast-enhanced echocardiography. (1990) (214)
Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. (1997) (209)
Updated clinical classification of pulmonary hypertension. (2009) (197)
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. (2009) (194)
Accuracy of doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates (2000) (183)
Unexplained pulmonary hypertension in chronic myeloproliferative disorders. (2001) (175)
Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease. (1996) (174)
Hepatopulmonary syndrome: An evolving perspective in the era of liver transplantation (1990) (168)
Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. (2002) (168)
Cardiac dysrhythmia following pneumonectomy. Clinical correlates and prognostic significance. (1987) (153)
Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. (2008) (140)
Pulmonary aspects of chronic liver disease and liver transplantation. (1985) (132)
Pulmonary Hypertension Is Associated With Reduced Patient Survival After Kidney Transplantation (2008) (128)
Hepatopulmonary syndrome versus portopulmonary hypertension: Distinctions and dilemmas (1997) (128)
Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. (1990) (124)
Hepatopulmonary syndrome: Favorable outcomes in the MELD exception era (2013) (123)
Severe hypoxemia associated with liver disease: Mayo Clinic experience and the experimental use of almitrine bismesylate. (1987) (120)
Severe hypoxemia and liver disease. (1989) (116)
Pulmonary aspects of liver disease and liver transplantation. (1989) (112)
Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. (1995) (111)
Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. (2011) (109)
The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. (2005) (107)
Effect of effort on measurement of forced expiratory volume in one second. (1987) (101)
Pulmonary hypertension in patients with interstitial lung diseases. (2007) (97)
Pulmonary arteriovenous malformations. (2013) (95)
Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. (2013) (93)
Model for end‐stage liver disease (MELD) exception for hepatopulmonary syndrome (2006) (93)
Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. (2004) (89)
Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. (1999) (86)
Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. (2004) (84)
Hepatopulmonary syndromes (2000) (83)
Hepatopulmonary syndrome and portopulmonary hypertension (2001) (81)
Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. (2019) (78)
Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. (2010) (76)
Model for end‐stage liver disease (MELD) exception for portopulmonary hypertension (2006) (75)
Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal Bleeding (2018) (75)
Highlights of the ERS Task Force on pulmonary-hepatic vascular disorders (PHD). (2005) (74)
A spectrum of pulmonary vascular pathology in portopulmonary hypertension (2000) (73)
Hepatopulmonary syndrome: Recent literature (1997 to 1999) and implications for liver transplantation (2000) (70)
Is severe arterial hypoxaemia due to hepatic disease an indication for liver transplantation? A new therapeutic approach. (1994) (70)
An official American Thoracic Society Statement: pulmonary hypertension phenotypes. (2014) (68)
Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. (2011) (65)
Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. (1999) (65)
Portopulmonary hypertension: state of the art. (2008) (63)
Successful liver transplantation in patients with mild to moderate pulmonary hypertension. (1993) (62)
Endothelium-derived relaxing factor in pulmonary and renal circulations during hypoxia. (1992) (60)
Screen for portopulmonary hypertension, especially in liver transplant candidates. (2008) (59)
Liver Transplantation for Hepatopulmonary Syndrome: A Ten-Year Experience in Paris, France. (2003) (57)
Pulmonary Vascular Complications of Liver Disease. (2017) (54)
Pulmonary hypertension: diagnostics and therapeutics. (2000) (52)
The Prevalence of Alpha-1 Antitrypsin Deficiency Among Patients Found to Have Airflow Obstruction (2012) (51)
Pulmonary complications of orthotopic liver transplantation. (1993) (49)
Outcomes for recipients of liver transplantation for alpha‐1‐antitrypsin deficiency–related cirrhosis (2013) (49)
Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. (1999) (47)
Hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. (2005) (46)
Predictors of Waitlist Mortality in Portopulmonary Hypertension (2017) (45)
Clinical management of hepatopulmonary syndrome. (1993) (45)
Evolving dilemmas and management of portopulmonary hypertension. (2006) (44)
A prospective study of pulmonary function and gas exchange following liver transplantation. (1992) (41)
Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. (2005) (41)
Arterial oxygenation associated with portopulmonary hypertension. (2002) (39)
North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. (2021) (38)
Health‐related quality of life and survival in liver transplant candidates (2010) (36)
Serotonin transporter polymorphisms in patients with portopulmonary hypertension. (2009) (35)
Frequency and Outcomes of Patients With Increased Mean Pulmonary Artery Pressure at the Time of Liver Transplantation (2017) (35)
Portopulmonary hypertension: Diagnostic advances and caveats (2003) (34)
Liver transplantation for pulmonary vascular complications of pediatric end-stage liver disease. (2008) (33)
Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation (2008) (32)
Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival (2015) (29)
Hepatopulmonary syndrome: what are we learning from interventional radiology, liver transplantation, and other disorders? (1995) (29)
Identifying the presence of clinically significant hepatic involvement in hereditary haemorrhagic telangiectasia using a simple clinical scoring index. (2014) (29)
Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia. (2016) (28)
Formation of a national database on pulmonary hypertension and hepatopulmonary syndrome in chronic liver disease. (1997) (28)
Azathioprine-associated pulmonary dysfunction. (1983) (28)
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience (2019) (27)
Portopulmonary hypertension and the issue of survival (2005) (27)
Doppler echocardiography-right heart catheterization relationships in patients with idiopathic pulmonary fibrosis and suspected pulmonary hypertension. (2008) (27)
Caveats concerning hepatopulmonary syndrome. (2001) (26)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ILOPROST INHALATION IN ADULTS WITH ABNORMAL PULMONARY ARTERIAL PRESSURE AND EXERCISE LIMITATION ASSOCIATED WITH IDIOPATHIC PULMONARY FIBROSIS (2007) (26)
Late recurrence and rapid evolution of severe hepatopulmonary syndrome after liver transplantation. (1999) (26)
Treatment Barriers in Portopulmonary Hypertension (2018) (25)
What’s new in the treatment of portopulmonary hypertension? (2015) (25)
Inflammatory bowel diseases, chronic liver diseases and the lung (2016) (25)
Portopulmonary Hypertension (2012) (24)
Bronchogenic cyst causing atrial fibrillation by impinging the right inferior pulmonary vein. (2006) (23)
How should we treat portopulmonary hypertension? (2006) (22)
Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial. (2020) (22)
Pulse Oximetry Is Insensitive for Detection of Hepatopulmonary Syndrome in Patients Evaluated for Liver Transplantation (2019) (22)
Alpha 1-Antitrypsin Deficiency Carriers , Tobacco Smoke , Chronic Obstructive Pulmonary Disease , and Lung Cancer Risk (2008) (21)
Primary biliary cirrhosis: Relation between hepatic function and pulmonary function in patients who never smoked (1991) (21)
BMP 9/10 in Pulmonary Vascular Complications of Liver Disease. (2020) (21)
Alpha1-Antitrypsin Deficiency Carriers, Serum Alpha 1-Antitrypsin Concentration, and Non-small Cell Lung Cancer Survival (2011) (20)
Pulmonary hypertension, (high) risk of orthotopic liver transplantation, and some lessons from “primary” pulmonary hypertension (2002) (20)
Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies (2018) (20)
High Rates of Bleeding Complications among Hospitalized Patients with Hereditary Hemorrhagic Telangiectasia in the United States. (2016) (20)
Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled Trial (2019) (18)
Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2) (2020) (18)
Recent pulmonary observations in alpha 1-antitrypsin deficiency, primary biliary cirrhosis, chronic hepatitis C, and other hepatic problems. (1996) (18)
A Pulmonary Vascular Complication of Liver Disease (1996) (18)
Pulmonary Complications of Portal Hypertension. (2019) (17)
Pathophysiology of arterial hypoxemia in advanced liver disease. (1996) (16)
The impact of left ventricular hypertrophy on survival in candidates for liver transplantation (2014) (16)
Portopulmonary hypertension. (2014) (16)
Successful coil embolization of mediastinal bronchial artery aneurysm. (2010) (16)
Liver Transplantation for Hepatopulmonary Syndrome (HPS): What Is the MESSAGE? (2008) (15)
Management of pulmonary complications in pretransplant patients. (2011) (15)
Hepatopulmonary syndrome. (2018) (15)
Hepatopulmonary Syndrome: Monitoring at Your Fingertip (2011) (14)
Clinical Impact of Intrapulmonary Vascular Dilatation in Candidates for Liver Transplant (2017) (14)
Liver Transplantation Trends and Outcomes for Hereditary Hemorrhagic Telangiectasia in the United States. (2019) (14)
Portopulmonary Hypertension: Understanding Pulmonary Hypertension in the Setting of Liver Disease (2004) (14)
Agnogenic Myeloid Metaplasia with Pleural Extramedullary Leukemic Transformation (2004) (14)
Portopulmonary hypertension. (2007) (14)
Hepatopulmonary Disorders: Gas Exchange and Vascular Manifestations in Chronic Liver Disease. (2018) (13)
Clinical Outcomes After Liver Transplantation in Patients With Portopulmonary Hypertension (2020) (13)
Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes (2019) (13)
Current Approach to the Diagnosis and Management of Portopulmonary Hypertension (2016) (12)
Pulmonary alveolar proteinosis. (2012) (12)
A prospective study of airway reactivity before bone marrow transplantation. (1990) (12)
Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease (2020) (12)
Outcomes of Liver Transplantation in Treated Portopulmonary Hypertension Patients With a Mean Pulmonary Arterial Pressure ≥35 mm Hg (2020) (12)
Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis (2020) (11)
Hepatopulmonary syndrome and portopulmonary hypertension (2002) (10)
Hepatopulmonary syndrome and liver transplantation (2000) (10)
Portopulmonary hypertension: Formidable dual threat versus hopeful dual therapy (2014) (10)
Hepatopulmonary syndrome and extrahepatic vascular abnormalities (2001) (10)
Tracheal myxoma: a rare benign tracheal tumor. (2004) (9)
The Myths and Realities of Portopulmonary Hypertension (2020) (9)
Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry (2020) (9)
Portopulmonary hypertension: the next step. (1997) (8)
Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure: Significant Inter-Individual Variability in the Need for Maintenance Therapy. (2020) (8)
Transthoracic echocardiography screening for the detection of portopulmonary hypertension: A work in progress (2013) (8)
Cardiovascular collapse induced by position-dependent pulmonary vein occlusion in a patient with fibrosing mediastinitis. (2005) (8)
Plasma levels of S100A4 in portopulmonary hypertension (2009) (7)
The distinct concepts and implications of hepatopulmonary syndrome and portopulmonary hypertension. (2005) (7)
Effect of Center Volume on Outcomes in Hospitalized Patients With Hereditary Hemorrhagic Telangiectasia. (2016) (6)
Liver and lung: Hepatopulmonary syndrome (2002) (6)
Impact of Age on Outcomes in Hospitalized Patients with Hereditary Hemorrhagic Telangiectasia (2018) (6)
Subspecialty clinics : Pulmonary and critical care medicine : Hepatopulmonary syndrom with progressive hypoxemia as an indication for liver transplantation : Case reports and literature review (1997) (6)
Survival benefits of liver transplant in severe hepatopulmonary syndrome. (2013) (6)
Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy (1995) (6)
Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial (2018) (6)
Gender Differences in Portopulmonary Hypertension. (2020) (5)
Alpha 1-Antitrypsin Deficiency Allele Carriers among Lung Cancer Patients 1 (1999) (5)
Arteriovenous malformations and hepatopulmonary syndrome (2004) (5)
Editorial: Pulmonary hypertension, (high) risk of orthotopic liver transplantation, and some lessons from "primary" pulmonary hypertension. (2002) (5)
Hepatopulmonary syndrome. (1993) (5)
Outcomes of liver transplantation in patients with hepatopulmonary syndrome in the pre and post-MELD eras: A systematic review. (2021) (5)
Relationship between portopulmonary hypertension and splenectomy: Mayo Clinic experience and review of published works (2017) (4)
Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis (2021) (4)
Association of α 1 Antitrypsin Phenotype and Development of Advanced Liver Disease and Pulmonary Complications Before and After Liver Transplantation. (2020) (4)
Continuing medical education as viewed by medical students. (1979) (4)
Portopulmonary hypertension and liver transplantation: A duo in question (2016) (4)
Pulmonary Complications of Portal Hypertension (2019) (4)
Bubble Trouble in COVID-19 (2020) (4)
The Liver-Lung Vascular Connection (2017) (4)
Many faces of portopulmonary hypertension. (2005) (3)
Preoperative Assessment and Management of Liver Transplant Candidates With Portopulmonary Hypertension (2013) (3)
Hepatopulmonary syndrome (2018) (3)
Discordant alpha-1 antitrypsin phenotype and genotype results in a liver transplant patient. (2010) (3)
Prevalence and Impact of Restrictive Lung Disease in Liver Transplant Candidates (2020) (3)
Mending the MELD: An in-depth review of the past, present, and future portopulmonary hypertension MELD exception. (2022) (3)
Portopulmonary hypertension: Diagnostic advances and caveats: Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study (2003) (3)
Pulmonary Complications Associated with Portal Hypertension (2005) (3)
ECMO and POPH: More Help for the Right Heart (2020) (2)
ICU and Hospital Outcomes in Patients with Hepatopulmonary Syndrome Undergoing Liver Transplantation (2022) (2)
INHALED NITRIC OXIDE REDUCES PULMONARY ARTERY PRESSURE IN PORTOPULMONARY HYPERTENSION (1998) (2)
Pulmonary manifestations of chronic liver disease (2000) (2)
131 Pulmonary vascular complications of liver disease: survival analysis of 140 patients evaluated at mayo clinic (2003) (2)
SEQUENTIAL HEPATOPULMONARY SYNDROME AND PORTOPULMONARY HYPERTENSION IN A LIVER TRANSPLANT CANDIDATE (2007) (2)
Lung function and the complications of bone marrow transplantation. (1992) (2)
Hepatopulmonary syndrome. (1991) (2)
Identifying High Risk of Sleep-Disordered Breathing in Patients With Idiopathic Pulmonary Fibrosis (2010) (1)
Portopulmonary hypertension: May we agree to disagree? (2023) (1)
ICU and Hospital Outcomes of Patients with Hepatopulmonary Syndrome Undergoing Liver Transplantation (2020) (1)
Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypertension Association Registry. (2022) (1)
Exploring the Spectrum of Pathology and Treatment in Portopulmonary Hypertension: Four Experts Address the Toughest Questions (2004) (1)
Treatment of Portopulmonary Hypertension With Macitentan in Patients With Cirrhosis. (2019) (1)
Improving hemodynamics pre-liver transplantation: The role of epoprostenol (2003) (1)
Exercise-Echocardiography-Derived Pulmonary Artery Pressure Slope in Borderline and Mild to Moderate Pulmonary Arterial Hypertension (2008) (1)
Liquid Chromatography-Tandem Mass Spectrometry-Based α1-Antitrypsin (AAT) Testing. (2020) (1)
Portopulmonary Hypertension in Nontransplanted Patients: Results of the Largest US Single-Institution Registry. (2022) (1)
Admission data: their use in health planning, legislative presentations, and premedical programs. (1981) (1)
Liver and lung: How to manage portopulmonary hypertension (2002) (1)
Hepatopulmonary syndrome. (1991) (1)
Abstract 16424: Reliability and Validity of Grading of Intra-Pulmonary Shunting by Contrast Transthoracic Echocardiography in Hepatopulmonary Syndrome (2010) (1)
Chapter 9 – Portopulmonary Hypertension (2006) (1)
Hepatic and Biliary Disease (2012) (1)
Pathology and Management of Portopulmonary Hypertension (2011) (1)
Portopulmonary hypertension: A consequence of portal hypertension (2012) (1)
Short and Long Termoxygenation Outcomes After Liver Transplantation for Hepatopulmonary Syndrome (2020) (1)
An Empirical Approach to Projecting Regional Blood Need (1977) (0)
Getting dark, too dark to see. Authors' reply (2005) (0)
Portopulmonary Hypertension: Natural History, Medical Therapy, Transplantation, And Survival (2010) (0)
175 RISK FACTORS, INCIDENCE, AND TIME TO ONSET FOR THE DEVELOPMENT OF PULMONARY HYPERTENSION AFTER LIVER TRANSPLANTATION FOR HEPATOPULMONARY SYNDROME (2021) (0)
Mending the Model for End‐Stage Liver Disease: An in‐depth review of the past, present, and future portopulmonary hypertension Model for End‐Stage Liver Disease exception (2022) (0)
Transplantation Anesthesia Hepatopulmonary SyndromeVA Liver-Induced Lung Vascular Disorder (2009) (0)
P17 Pharmacokinetics of macitentan in patients with portopulmonary hypertension: findings from the PORTICO sub-study (2018) (0)
Left Ventricular Diastolic Dysfunction in Advanced Liver Disease (2020) (0)
Hemodynamics of Pulmonary Hypertension in the Setting of Hereditary Hemorrhagic Telangiectasia (2014) (0)
Cardiopulmonary examination (2016) (0)
Outcomes of Liver Transplantation for Hereditary Hemorrhagic Telangiectasia (HHT).: Abstract# C1969 (2014) (0)
Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes (2022) (0)
Quality of Life as Assessed by the SYMPACT Questionnaire in Patients with Chronic Thromboembolic Pulmonary Hypertension (2020) (0)
Evidence Rofl umilast Reduces Severe Exacerbations (2015) (0)
19. Portopulmonary hypertension (2015) (0)
Estrogen Metabolism in Portopulmonary Hypertension (POPH): A Case-Control Study (2019) (0)
1 Hepatopulmonary syndrome (2011) (0)
Erratum: The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction (COPD: Journal of Chronic Obstructive Pulmonary Disease 9:4 (352-358)) (2013) (0)
Pulmonary Alterations in Chronic Liver Failure (2011) (0)
Hepatopulmonary syndrome: Long-term survival in the Mayo Clinic experience (2012) (0)
Alpha-One Antitrypsin Deficiency: Survival And Pulmonary Function After Orthotopic Liver Transplantation In ZZ And SZ Phenotypes (2011) (0)
The feasibility and value of assessing patient‐reported outcomes in pulmonary arterial hypertension (2022) (0)
RISK FACTORS FOR COPD IN LIVER TRANSPLANT CANDIDATES (2007) (0)
Role of Suppression of Tumorigenecity (ST2) in Pulmonary Vascular Complications of Liver Disease (2019) (0)
CNS complications in pulmonary arteriovenous malformations: Response (2014) (0)
Six-Minute walk distance predicts outcomes in liver transplant candidates (2023) (0)
Relating health planning concepts to medical students. (1979) (0)
Using PAH-SYMPACT to Assess Quality of Life in Patients with Pulmonary Hypertension Associated with Chronic Lung Disease (2022) (0)
Hepatocelluar and liver transplantation (2000) (0)
Genetic Variation In Heme Oxygenase 1 Is Associated With Severity Of Oxygenation Abnormality In Patients With Hepatopulmonary Syndrome (2011) (0)
Erratum: α1-antitrypsin and neutrophil elastase imbalance and lung cancer risk (Chest (July 2005) 128 (445-452)) (2006) (0)
It's Complicated: Dyspnea and Hypoxemia in a Patient With Portal Hypertension (2023) (0)
Hepatopulmonary Syndrome* ClinicalObservations andLackof Therapeutic ResponseToSomatostatin Analogue (2017) (0)
Sex Differences in Portopulmonary Hypertension (2020) (0)
Title: The Relationship Between Portopulmonary Hypertension and Splenectomy: Mayo Clinic Experience and Literature Review Short Title: Portopulmonary hypertension and splenectomy (2017) (0)
LINICAL ADVANCES IN LIVER , PANCREAS , ND BILIARY TRACT mpact of Hepatopulmonary Syndrome on Quality of Life and Survival in iver Transplant Candidates (2008) (0)
Hepatopulmonary syndrome [16] (1991) (0)
Pulmonary Evaluation of Liver Transplant Candidates (2019) (0)
PSEUDOMITRAL STENOSIS DUE TO PULMONARY VENOUS OBSTRUCTION BY NONCALCIFIED FIBROSING MEDIASTINITIS ASSOCIATED WITH HISTOPLASMOSIS (2006) (0)
Severe Hypoxemia and Liver Disease (1990) (0)
ELECTROCARDIOGRAPHIC CHARACTERISTICS OF PULMONARY HYPERTENSION IN THE SETTING OF HEREDITARY HEMORRHAGIC TELANGIECTASIA (2015) (0)
Determinants of Health-Related Quality of Life as Assessed by the PAH-SYMPACT Questionnaire in Patients with Pulmonary Arterial Hypertension (2020) (0)
Cardiac index and hepatopulmonary syndrome in liver transplantation candidates: The pulmonary vascular complications of liver disease study (2023) (0)
Syndrome* Current Concepts in Diagnostic and Therapeutic Considerations (2017) (0)
Do Late Bubbles Correspond to Early Hepatopulmonary Syndrome? (2017) (0)
Feedback from admission committees to applicant interviewers. (1978) (0)
communications tothe editor (2017) (0)
Prevalence and Implications of Positive Contrast Transthoracic Echocardiography in Portopulmonary Hypertension (2013) (0)
Table of Contents (2020) (0)
Smoking and Outcomes in Candidates for Liver Transplantation: PVCLD2 (2023) (0)
Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database (2020) (0)
Temporal Trends in Portopulmonary Hypertension (POPH) Model for End Stage Liver Disease (MELD) Exceptions (2022) (0)
Resolution of portopulmonary hypertension (POPH) following liver transplantation (2012) (0)
The Utility of Serial Right Heart Catheterizations in Patients with Model for End Stage Liver Disease Exceptions for Portopulmonary Hypertension (0)
Pulmonary alveolar proteinosis clinico-Pathologic conferences (2012) (0)
Review of Portopulmonary Hypertension Prevalence at Mayo Clinic in Arizona, Florida, and Minnesota (2023) (0)
Hemodynamic Response to Inhaled Nitric Oxide in Patients with Pulmonary Hypertension and Chronic Kidney Disease: A Retrospective Cohort Study (2022) (0)
Chapter 59 – Hepatic and Biliary Disease (2008) (0)
Plasma Endothelin-1 And Pulmonary Vascular Complications Of Liver Disease (2010) (0)
717: ASSOCIATION OF PULMONARY HYPERTENSION AND MORTALITY IN PATIENTS WITH VENTILATOR ASSOCIATED EVENTS (2014) (0)

This paper list is powered by the following services:

Michael Joseph Krowka's Academic­Influence.com Rankings

Why Is Michael Joseph Krowka Influential?

Michael Joseph Krowka's Published Works

Published Works

Michael Joseph Krowka's AcademicInfluence.com Rankings